Clinical Study of Meplazumab to Treat With Malaria
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study will be conducted to explore the dose regimen in humans and to evaluate
the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and toxicological
effects of meplazumab in healthy subjects, thus providing a new macromolecule antibody drug
for the prevention and treatment of P. falciparum infection.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd